Unconjugated hyperbilirubinemia occurs in almost all premature infants and is potentially neurotoxic. Treatment is based on total serum bilirubin (TSB), but treatment thresholds are not evidence based.
Free bilirubin (Bf), i.e. not bound to albumin, seems a better parameter for bilirubin neurotoxicity, but measurements of Bf are not available in clinical practice. The bilirubin/ albumin (B/A) ratio is considered as a surrogate parameter for Bf and as an interesting additional parameter in the management of hyperbilirubinemia. We reviewed the evidence supporting the use of B/ A ratios for predicting bilirubin-induced neurological dysfunction (BIND) including neurodevelopmental delay in jaundiced premature infants (gestational age less than 32 weeks).
We performed a literature search and review 6 publications regarding B/ A ratios in the management and outcome of jaundiced premature infants. No prospective clinical trials exist demonstrating that bilirubin-induced neurotoxicity is reduced or that unnecessary treatment is avoided by using the B/A ratio in addition to TSB.
Recently, a randomized controlled trial evaluating the effect of the additional use of the B/A ratio on neurodevelopmental outcome in jaundiced premature infants has been initiated. Based on the prevailing evidence many authorities suggest that the additional use of the B/A ratio may be valuable when evaluating jaundiced premature infants.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.